Quest revenues grow as company meets changing demands

CHICAGO--Quest Diagnostics grew its revenues by 5 percent during the first quarter of 2015, largely by offering products that address the growing demand for interoperability, patient engagement, personalized medicine and continuity of care.

With 20 billion data points stored, Quest is in a unique position to make data actionable. During the 2015 Annual HIMSS Conference & Exhibition, the company displayed the latest in its Care 360 line, Interactive Insights which offers "next generation lab reports," said Tom Wagner, vice president of Healthcare Technology Solutions.

In recent years, Quest entered into a collaboration with the University of California at San Francisco to accelerate the translation of biomedical research into advanced diagnostics in the field of precision medicine. The collaboration combines the research discoveries and capabilities of UCSF with Quest's national testing database and technical and clinical development capability.

Quest also has pilots with two big payers underway because so many are interested in going after the accountable care market, said Wagner. "Everyone wants some part of the lab report." By looking at both lab values and medications, one can tell what diseases are prevalent in a given group of patients. 

Quest has addressed patient engagement with its patient portal, MyQuest. Patients can access their lab reports and take the information to any provider. Rather than help people become "alarmist," the company is interested in "helping patients have better dialogue."

Privacy and security of all that data is "a significant problem that we take seriously," Wagner said. Everything is secure in motion and at rest as well as subject to penetration and vulnerability testing. The concern "hangs in the background" and "makes everyone focus." 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.